郵箱: lihong01@sinh.ac.cn lihong01@sibs.ac.cn
電話: +86-21-54920348
研究組主頁(yè): https://lihonglab.github.io/
所屬部門: 計(jì)算生物學(xué)重點(diǎn)實(shí)驗(yàn)室
2021-至???今：中國(guó)科學(xué)院上海營(yíng)養(yǎng)與健康研究所，研究員
2020-2021年：中國(guó)科學(xué)院-馬普學(xué)會(huì)計(jì)算生物學(xué)伙伴研究所，研究員
2014-2019年：中國(guó)科學(xué)院上海生命科學(xué)研究院，副研究員
2013-2014年：中國(guó)科學(xué)院上海生命科學(xué)研究院，助理研究員
2010-2013年：美國(guó)系統(tǒng)生物學(xué)研究所，博士后
2005-2010年：中國(guó)科學(xué)院上海生命科學(xué)研究院，生物信息學(xué)博士
2001-2005年：中南大學(xué)，信息與計(jì)算科學(xué)學(xué)士
系統(tǒng)生物學(xué)
（1）單細(xì)胞和空間組學(xué)分析方法，應(yīng)用于解析腫瘤和肝臟疾病的微環(huán)境，鑒定新細(xì)胞亞型和細(xì)胞狀態(tài)改變的關(guān)鍵基因、分析細(xì)胞空間分布和相互作用。
（2）整合多模態(tài)數(shù)據(jù)的人工智能方法，應(yīng)用于疾病標(biāo)志物篩選、腫瘤個(gè)體化用藥和計(jì)算病理研究。
（3）癌癥基因組圖譜和演化，研究癌癥發(fā)生發(fā)展過(guò)程中基因組圖譜的變化，重構(gòu)癌癥的進(jìn)化路徑，并尋找關(guān)鍵基因。
1.?Lin P#, Yan X, Jing S, Wu Y, Shan Y, Guo W, Gu J, Li Y, Zhang H, Li H*. Single-cell and spatially resolved transcriptomics for liver biology. Hepatology?2023 Apr 3. doi: 10.1097/HEP.0000000000000387.?
2.?Li L#, Cui L#, Lin P#, Liu Z, Bao S, Ma X, Nan H, Zhu W, Cen J, Mao Y, Ma X, Jiang L, Nie Y, Ginhoux F, Li Y*, Li H*, Hui L*. Kupffer-cell-derived IL-6 is repurposed for hepatocyte dedifferentiation via activating progenitor genes from injury-specific enhancers.?Cell Stem Cell?2023, S1934-5909(23)00009-7.?
3.?Shen B#, Feng F#, Li K, Lin P, Ma L, &?Li?H*. A systematic assessment of deep learning methods for drug response prediction: from in vitro to clinical applications.?Brief Bioinform.?2023, 24(1):bbac605.
4.?Yang J#, Lin P#, Yang M#, Liu W, Fu X, Liu D, Tao L, Huo Y, Zhang J, Hua R, Zhang Z*, Li Y*, Wang L*, Xue J*, Li H*, Sun Y*. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma. Genome biology?2021, 22(1): 4.
5.?Feng F, Shen B, Mou X, Li Y, Li H*. Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine. J Genet Genomics. 2021;48(7):540-551.
6.?Hu B#,?Li H#, Guo W, Sun YF, Zhang X, Tang WG, Yang LX, Xu Y, Tang XY, Ding GH, Qiu SJ, Zhou J, Li YX, Fan J, Yang XR. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.?Int J Cancer?2020 Mar 15;146(6):1606-1617.
7.?Qiu Z#,?Li H#, Zhang Z#, Zhu Z, He S, Wang X, Wang P, Qin J, Zhuang L, Wang W, Xie F, Gu Y, Zou K, Li C, Li C, Wang C, Cen J, Chen X, Shu Y, Zhang Z, Sun L, Min L, Fu Y, Huang X, Lv H, Zhou H, Ji Y, Zhang Z, Meng Z, Shi X, Zhang H*, Li Y*, Hui L*. A Pharmacogenomic Landscape in Human Liver Cancers.?Cancer Cell?2019 Aug 12;36(2):179-193.e11.
8.?Li W#, Yang L#, He Q, Hu C, Zhu L, Ma X, Ma X, Bao S, Li L, Chen Y, Deng X, Zhang X, Cen J, Zhang L, Wang Z, Xie WF,?Li H*, Li Y*, Hui L*. A Homeostatic Arid1a-Dependent Permissive Chromatin State Licenses Hepatocyte Responsiveness to Liver-Injury-Associated YAP Signaling.?Cell stem cell?2019 Jul 3;25(1):54-68.e5.
9.?Cheng J#, Wei D, Ji Y, Chen L, Yang L, Li G, Wu L, Hou T, Xie L, Ding G,?Li H*, Li Y*. Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers.?Genome Med?2018 May 30;10(1):42.
10.?Hu H#,?Li H#, Jiao F, Han T, Zhuo M, Cui J, Li Y*, Wang L*. Association of a novel point mutation in MSH2 gene with familial multiple primary cancers.?J Hematol Oncol?2017 Oct 3;10(1):158.
11.?Li H#, Glusman G, Hu H, Caballero J, Hubley R, Witherspoon D, Guthery SL, Mauldin DE, Jorde LB, Hood L, Roach JC*, Huff CD*. Relationship Estimation from Whole-Genome Sequence Data.?PLoS Genet?2014 Jan 30;10(1):e1004144.
官方微信
